Related Experiment Video

Updated: Jul 18, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

The management of patients with limited-stage classical Hodgkin lymphoma

Mary K Gospodarowicz1, Ralph M Meyer

  • 1The Princess Margaret Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada.

Hematology. American Society of Hematology. Education Program
|November 25, 2006
PubMed

Insights

Limited-stage Hodgkin lymphoma patients achieve over 90% disease control. Management now focuses on minimizing long-term treatment risks by balancing chemotherapy and radiation therapy trade-offs.

Area of Science:

  • Oncology
  • Hematology
  • Radiation Oncology

Background:

  • Limited-stage Hodgkin lymphoma (HL) affects approximately one-third of classical HL patients.
  • Long-term disease control is achievable in over 90% of these patients.
  • Current management must prioritize reducing treatment-related long-term risks.

Purpose of the Study:

  • To evaluate treatment strategies for limited-stage Hodgkin lymphoma.
  • To balance disease control with the reduction of long-term treatment toxicities.
  • To inform clinical decision-making regarding chemotherapy and radiation therapy options.

Main Methods:

  • Review of current treatment modalities for limited-stage Hodgkin lymphoma.
  • Comparison of combined modality therapy (chemotherapy + involved-field radiation) versus single-modality chemotherapy (ABVD).
  • Assessment of trade-offs between efficacy and long-term adverse effects.

Main Results:

  • Combined modality therapy and ABVD chemotherapy are primary treatment options.
  • Treatment choice involves balancing disease control rates with potential late effects.
  • Over 90% long-term disease control is a realistic expectation.

Conclusions:

  • Management of limited-stage Hodgkin lymphoma requires careful consideration of long-term risks.
  • Optimizing treatment strategies aims to maximize cure rates while minimizing late toxicities.
  • Personalized treatment selection is crucial to balance oncologic outcomes and patient quality of life.

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...